This increased expression of PKM2 confers drug resistance in pancreatic ductal adenocarcinoma, suggesting that PKM2 and PTBP1 could serve as potential therapeutic targets to enhance the response to chemotherapy [253]. Here, PKM is linked to pancreatic ductal adenocarcinoma.